Tardive Dyskinesia: Progression

Stacy Finkbeiner, US Medical Director at Teva Pharmaceuticals, explains our understanding of whether TD is a progressive condition. She is one of the authors of the study, Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.

Presented by The Journal of Clinical Psychiatry ​ @psychiatristcns